NANBIOSIS joined BSIFS2025, presenting its ICTS capabilities and strengthening collaboration with national and international Big Science infrastructures.
Madrid, December 2025 — Last week, NANBIOSIS participated in the Big Science Industry Forum Spain 2025 (BSIFS2025), the first national forum designed to strengthen Spain’s Big Science industry and promote collaboration between research infrastructures, companies, and scientific institutions. The event—organised by CDTI Innovation, INDUCIENCIA, and INEUSTAR—highlighted Spain’s technological leadership and its role in major international scientific projects.
Held over two days, BSIFS2025 gathered representatives from leading global research infrastructures in particle physics, fusion, and astronomy, including CERN, ITER and F4E, and ESO, alongside key national ICTS facilities. The forum offered a comprehensive programme featuring procurement updates, technological trends, networking spaces, company exhibitions, and a poster area showcasing research capabilities.
NANBIOSIS was present within the ICTS stand of the Ministry of Science, Innovation and Universities, which received a visit from the Minister, Diana Morant. The infrastructure also presented a poster detailing its services and technological capacities in biomedical research and nanomedicine.
Throughout the event, NANBIOSIS engaged with industry representatives, research centres, and other large scientific facilities, strengthening partnerships and exploring new opportunities for collaboration. Participation in BSIFS2025 reinforced the key role of NANBIOSIS within Spain’s scientific ecosystem and its contributions to innovation, technology transfer, and advanced research services.
What is NANBIOSIS?
The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).
In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.
NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:
